EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock closed at $6.12 on 11/21/23 after a major decline of -13.4%. The stock has declined -4.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
EYPT’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.
EyePoint Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. EyePoint Pharmaceuticals has a very low Appreciation Score of 10 but a very high Power Rating of 97, triggering the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment